Conv. Plasma
Nigella Sativa
Peg.. Lambda

All vitamin D studies
Meta analysis
Home COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Vitamin D Supplementation in COVID-19 Patients: A Clinical Case Series

Ohaegbulam et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001222
Oct 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Small case study of 4 vitamin D deficient patients with 2 patients treated with cholecalciferol 1,000 IU daily and two patients treated with ergocalciferol 50,000 IU daily for 5 days (high dose), showing that patients receiving high dose therapy had improved clinical recovery, with shorter lengths of stay, lower oxygen requirements, and a reduction in inflammatory marker status.
Ohaegbulam et al., 31 Oct 2020, peer-reviewed, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Vitamin D Supplementation in COVID-19 Patients: A Clinical Case Series
MD Kim C Ohaegbulam, PhD Mohamed Swalih, Pranavkumar Do, MBBS Miriam A Patel, MD, FACP, MBA Richard Smith, MD Perrin
Background: Coronavirus disease 2019 (COVID-19) has infected more than 4.4 million people and caused more than 300,000 deaths partly through acute respiratory distress syndrome with propensity to affect African American and Hispanic communities disproportionately. Patients with worse outcomes have exhibited higher blood plasma levels of proinflammatory cytokines. Activation of the vitamin D receptor expressed on immune cells has been shown to directly reduce the secretion of inflammatory cytokines, such as interleukin-6, and indirectly affect C-reactive protein. Areas of Uncertainty: The significance of the vitamin D pathway in patients diagnosed with COVID-19. Therapeutic Innovation: Vitamin D supplementation in patients after diagnosis of COVID-19. Patients and Pharmacological Interventions: We report 4 vitamin D deficient patients diagnosed with COVID-19 in April 2020 who were provided with either cholecalciferol of 1000 IU daily (standard dose) or ergocalciferol 50,000 IU daily for 5 days (high dose) as part of supplementation. Clinical Outcomes: Patients that received a high dose of vitamin D supplementation achieved normalization of vitamin D levels and improved clinical recovery evidenced by shorter lengths of stay, lower oxygen requirements, and a reduction in inflammatory marker status. Conclusions: Vitamin D supplementation may serve as a viable alternative for curtailing acute respiratory distress syndrome in patients in underserved communities where resources to expensive and sought-after medications may be scarce. Randomized clinical trials will serve as an appropriate vessel to validate the efficacy of the therapeutic regimen and dissection of the pathway.
Beard, Bearden, Striker, Vitamin D and the antiviral state, J Clin Virol
Chen, Wu, Guo, Clinical and immunological features of severe and moderate coronavirus disease 2019, J Clin Invest
Grant, Giovannucci, The possible roles of solar ultraviolet-B radiation and vitamin D in reducing case-fatality rates from the 1918-1919 influenza pandemic in the United States, Dermatoendocrinol
Hu, Sun, Dai, Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis, J Clin Virol
Hui, Zhang, An, Higher serum procalcitonin and IL-6 levels predict worse diagnosis for acute respiratory distress syndrome patients with multiple organ dysfunction, Int J Clin Exp Pathol
Khoo, Chai, Koenen, Translating the role of vitamin D3 in infectious diseases, Crit Rev Microbiol
Lauer, Grantz, Bi, The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application, Ann Intern Med
Liu, Li, Zhou, Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?, J Autoimmun
Miroliaee, Salamzadeh, Shokouhi, The study of vitamin D administration effect on CRP and Interleukin-6 as prognostic biomarkers of ventilator associated pneumonia, J Crit Care
Nnoaham, Clarke, Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis, Int J Epidemiol
Pawar, Desai, Solomon, Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study, Ann Rheum Dis
Rejnmark, Bislev, Cashman, Non-skeletal health effects of vitamin D supplementation: a systematic review on findings from meta-analyses summarizing trial data, PLoS One
Shah, Sachdeva, Dodiuk-Gad, COVID-19 and racial disparities, J Am Acad Dermatol
Shine, De Beer, Pepys, Solid phase radioimmunoassays for human C-reactive protein, Clin Chim Acta
Wang, Hu, Hu, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, JAMA
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop